Neuronetics, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Neuronetics reported Q2 2026 total revenue of $41.6M (+9.1% YoY), with Greenbrook clinic revenue of $26.9M (+16.8% YoY) offsetting a 2.7% decline in NeuroStar revenue to $14.7M. Gross margin expanded to 51.1% from 46.6%, and adjusted EBITDA turned positive at $0.3M versus a loss of $5.6M in Q2 2025. Net loss narrowed to $3.4M ($0.05/share) from $10.1M ($0.15/share). The company appointed a new CFO (Nir Naor), promoted Cory Anderson to Greenbrook GM, and hired Rob Greene as VP Sales. FY2026 guidance: $160–164M revenue (+7–10%), 48–50% gross margin, operating expenses $91–96M (excluding ~$4M stock comp), cash burn of $10.5–14.5M.
Why this rating
Modest operational improvements, path to profitability tangible but fragile; $24.9M cash against $61.5M debt and ongoing burn raises solvency concerns. 9% growth modest vs. company size.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.